Business Context and Reporting Period
This Form 8-K is filed by OvaScience, Inc. (not Tempest Therapeutics, Inc.) on March 15, 2018. The report announces the financial results for the quarter and the full year ended December 31, 2017. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the body of this 8-K document.
Material Changes
No specific material changes or comparative data versus prior periods are detailed in the text of this filing. The document serves solely as a notification that results have been announced.
Guidance, Outlook, and Risks
The filing does not provide management commentary, guidance, outlook, or specific risk factors within the text. It explicitly states that the information in this report and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, limiting its incorporation by reference.
Investor Verification Checklist
- Verify the correct registrant name is OvaScience, Inc., as the input metadata incorrectly listed Tempest Therapeutics, Inc.
- Locate and review Exhibit 99.1 (Press Release dated March 15, 2018) to obtain actual financial figures for the quarter and year ended December 31, 2017.
- Confirm the status of the company as an emerging growth company, as the filing indicates this status was checked.
- Note that the financial data in this specific 8-K text is not deemed "filed" under Section 18 of the Exchange Act.